HalioDx designs and commercializes a unique range of immune scoring tests, whose first-in-class product is Immunoscore®. Considered a future diagnostic standard in Oncology, this biomarker has already demonstrated strong prognostic value in colon cancer. Immunoscore® technology integrates
Immunohistochemistry combined with Advanced imaging analysis. HalioDx develops also assays such
as Halioseek™ and Immunosign® to help stratifying patients for Immune-based therapies. HalioDx has a CLIA-certified laboratory (H1 2017) and executes biomarker studies in collaboration with biopharma companies.